Fearon算法在抗凝服务指导下华法林管理中的可行性研究

Q4 Medicine Thrombosis Update Pub Date : 2022-05-01 DOI:10.1016/j.tru.2022.100105
John Saunders , Sara R. Vazquez , Aubrey E. Jones , J. Michael Fearon , Paul Wegener , Aaron Wilson , Daniel M. Witt
{"title":"Fearon算法在抗凝服务指导下华法林管理中的可行性研究","authors":"John Saunders ,&nbsp;Sara R. Vazquez ,&nbsp;Aubrey E. Jones ,&nbsp;J. Michael Fearon ,&nbsp;Paul Wegener ,&nbsp;Aaron Wilson ,&nbsp;Daniel M. Witt","doi":"10.1016/j.tru.2022.100105","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Patients receiving warfarin who spend a lower proportion of time in therapeutic international normalized ratio (INR) range (TTR) have a higher risk of both bleeding complications and thromboembolic events. Using warfarin dosing algorithms is one intervention associated with improved INR stability.</p></div><div><h3>Objective</h3><p>To determine the feasibility of an individualized warfarin dosing algorithm (Fearon Algorithm) under anticoagulation management service (AMS) care and compare measures of INR control using the algorithm with standard care.</p></div><div><h3>Methods</h3><p>A pre/post intervention feasibility study consisting of the 12 months prior to patient enrollment (pre-study phase) and 6 months in which patients used the Fearon Algorithm under the supervision of an AMS pharmacist (AMS phase). The primary study outcome was the change in individual TTR.</p></div><div><h3>Results</h3><p>A total of 30 patients were enrolled in the study, 26 (87%) of whom successfully completed the AMS study phase using the Fearon Algorithm. Median corrected individual TTR increased significantly from 53% (IQR: 39%, 64%) during the year prior to enrollment to 63% (IQR: 57%, 73%) during the AMS phase (p &lt; 0.01) The uncorrected TTR also increased significantly from 52% (IQR: 39%, 64%) to 61% (IQR: 57%, 72%) (p &lt; 0.01). The Fearon Algorithm specified a smaller warfarin tablet strength in half the patients.</p></div><div><h3>Conclusion</h3><p>The Fearon Algorithm is feasible for an AMS to implement in patients receiving long-term warfarin therapy and appears to improve TTR.</p></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666572722000098/pdfft?md5=82b74936348d4288a8176e5ac06a5d19&pid=1-s2.0-S2666572722000098-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Feasibility study of the Fearon Algorithm in anticoagulation service guided warfarin management\",\"authors\":\"John Saunders ,&nbsp;Sara R. Vazquez ,&nbsp;Aubrey E. Jones ,&nbsp;J. Michael Fearon ,&nbsp;Paul Wegener ,&nbsp;Aaron Wilson ,&nbsp;Daniel M. Witt\",\"doi\":\"10.1016/j.tru.2022.100105\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Patients receiving warfarin who spend a lower proportion of time in therapeutic international normalized ratio (INR) range (TTR) have a higher risk of both bleeding complications and thromboembolic events. Using warfarin dosing algorithms is one intervention associated with improved INR stability.</p></div><div><h3>Objective</h3><p>To determine the feasibility of an individualized warfarin dosing algorithm (Fearon Algorithm) under anticoagulation management service (AMS) care and compare measures of INR control using the algorithm with standard care.</p></div><div><h3>Methods</h3><p>A pre/post intervention feasibility study consisting of the 12 months prior to patient enrollment (pre-study phase) and 6 months in which patients used the Fearon Algorithm under the supervision of an AMS pharmacist (AMS phase). The primary study outcome was the change in individual TTR.</p></div><div><h3>Results</h3><p>A total of 30 patients were enrolled in the study, 26 (87%) of whom successfully completed the AMS study phase using the Fearon Algorithm. Median corrected individual TTR increased significantly from 53% (IQR: 39%, 64%) during the year prior to enrollment to 63% (IQR: 57%, 73%) during the AMS phase (p &lt; 0.01) The uncorrected TTR also increased significantly from 52% (IQR: 39%, 64%) to 61% (IQR: 57%, 72%) (p &lt; 0.01). The Fearon Algorithm specified a smaller warfarin tablet strength in half the patients.</p></div><div><h3>Conclusion</h3><p>The Fearon Algorithm is feasible for an AMS to implement in patients receiving long-term warfarin therapy and appears to improve TTR.</p></div>\",\"PeriodicalId\":34401,\"journal\":{\"name\":\"Thrombosis Update\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2666572722000098/pdfft?md5=82b74936348d4288a8176e5ac06a5d19&pid=1-s2.0-S2666572722000098-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Thrombosis Update\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666572722000098\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thrombosis Update","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666572722000098","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

接受华法林治疗的患者在治疗性国际标准化比率(INR)范围(TTR)中花费的时间比例较低,出血并发症和血栓栓塞事件的风险较高。使用华法林给药算法是一种与改善INR稳定性相关的干预措施。目的探讨抗凝管理服务(AMS)护理下华法林个体化给药算法(Fearon算法)的可行性,并比较该算法与标准护理下的INR控制措施。方法进行干预前/干预后可行性研究,包括患者入组前12个月(预研究阶段)和患者在AMS药剂师监督下使用Fearon算法的6个月(AMS阶段)。主要研究结果是个体TTR的变化。结果共纳入30例患者,其中26例(87%)采用Fearon算法成功完成AMS研究阶段。校正后的中位个体TTR从入组前一年的53% (IQR: 39%, 64%)显著增加到AMS阶段的63% (IQR: 57%, 73%) (p <0.01)未校正的TTR也从52% (IQR: 39%, 64%)显著增加到61% (IQR: 57%, 72%) (p <0.01)。Fearon算法在一半患者中指定了较小的华法林药片强度。结论采用Fearon算法对长期接受华法林治疗的患者实施AMS是可行的,并能提高TTR。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Feasibility study of the Fearon Algorithm in anticoagulation service guided warfarin management

Background

Patients receiving warfarin who spend a lower proportion of time in therapeutic international normalized ratio (INR) range (TTR) have a higher risk of both bleeding complications and thromboembolic events. Using warfarin dosing algorithms is one intervention associated with improved INR stability.

Objective

To determine the feasibility of an individualized warfarin dosing algorithm (Fearon Algorithm) under anticoagulation management service (AMS) care and compare measures of INR control using the algorithm with standard care.

Methods

A pre/post intervention feasibility study consisting of the 12 months prior to patient enrollment (pre-study phase) and 6 months in which patients used the Fearon Algorithm under the supervision of an AMS pharmacist (AMS phase). The primary study outcome was the change in individual TTR.

Results

A total of 30 patients were enrolled in the study, 26 (87%) of whom successfully completed the AMS study phase using the Fearon Algorithm. Median corrected individual TTR increased significantly from 53% (IQR: 39%, 64%) during the year prior to enrollment to 63% (IQR: 57%, 73%) during the AMS phase (p < 0.01) The uncorrected TTR also increased significantly from 52% (IQR: 39%, 64%) to 61% (IQR: 57%, 72%) (p < 0.01). The Fearon Algorithm specified a smaller warfarin tablet strength in half the patients.

Conclusion

The Fearon Algorithm is feasible for an AMS to implement in patients receiving long-term warfarin therapy and appears to improve TTR.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Thrombosis Update
Thrombosis Update Medicine-Hematology
CiteScore
1.90
自引率
0.00%
发文量
33
审稿时长
86 days
期刊最新文献
Tissue factor (F3) gene variants and thrombotic risk among middle-aged and older adults: A population-based cohort study Catheter – related thrombosis in cancer patients: Data from the registry of thrombosis and nEoplasia of SEOM (TESEO) Usability study of the qLabs® FIB: A new point-of-care system for functional fibrinogen testing Nitrous oxide and VTE – no laughing matter Practical model for implementation of cancer-associated thrombosis prevention in the outpatient setting
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1